Rasagiline preclinical studies: Implications for neuroprotection

Formulary

Volumn 41, Issue SUPPL., 2006, Pages 25-30

  Ondo, William G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLORGYLINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; N (2 PROPYNYL) 1 INDANAMINE; RASAGILINE; SALAZOSULFAPYRIDINE; SELEGILINE;

BRAIN ISCHEMIA; CELL DEATH; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REOXYGENATION; REVIEW;

EID: 33748479049     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Jankovic J, Marsden CD. Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore, Md: Urban & Schwarzenberg; 1988;95-119.
2. Pahwa R. Pharmacologic management of Parkinson disease: initial therapy. Formulary. 2006;41:4-11.
3. Waters CH. Pharmacologic management of Parkinson disease: treatment of levodopa-associated "wearing off." Formulary. 2006;41:12-17.
4. Parkinson Study Group. Effects of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
5. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
6. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39:37-45.
7. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39:29-36.
8. Tabakman R, Lecht S, Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays. 2004;26:80-90.
9. Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of L-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994;56:742-749.
10. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem. 1997;68:434-436.
11. Oh C, Murray B, Bhattacharya N, Hollard D, Tatton WG. (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res. 1994;38;64-74.
12. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler B, Lazarovici P. Trembovler Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434:109-116.
13. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan] , a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506.
14. Am OB, Amit T, Youdim B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355:169-172.
15. Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 1999;58:456-463.
16. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998;9:703-707.
17. Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradfrod HF. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurons in culture. Neuroreport. 2000;11:3937-3941.
18. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366:127-135.
19. Speiser Z, Mayk AA, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106:593-606.
20. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004;187:455-459.
21. Youdim MB, Amit T, Yogev-Falach M, Am OB, Maruyama W, Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003;66:1635-1641.
22. Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav. 1998;60:387-393.
23. Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the nonhuman primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm. 2001;108:985-1009.
24. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J Neurochem. 2002;82:913-923.
25. Maruyama W, Akao Y, Youdim MB, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1R-and (S)-aminoindan, rasagiline, and TV 1022. J Neural Transm. 2000;60(suppl):171-186.
26. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem. 2004;89:1119-1125.
27. Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines induce anti-apoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther. 2002;301:753-764.
28. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105-108.
29. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 2002;16:1674-1676.
30. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 2000;67:577-585.
31. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem. 2001;78:727-735.
32. Fukuhara Y, Takeshima T, Kashiwaya Y, Shimoda K, Ishitani R, Nakashima K. GAPDH knockdown rescues mesencephalic dopaminergic neurons from MPP+-induced apoptosis. Neuroreport. 2001;12:2049-2052.
33. Maruyama W, Nitta A, Shamoto-Nagai M, et al. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappa-B transcription factor. Neurochem Int. 2004;44:393-400.
34. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch Neurol. 2004;61:561-566.
35. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.